Report ORR data for CELMoD agents
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- by 31 Dec 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“ORR 2021 (potentially registrational)”
What we found
Evidence strength A What the grades mean
The company presented data for CELMoD agents (iberdomide and CC-92480) at the ASH 2021 conference, fulfilling the commitment to report ORR data in 2021.
-
A Bristol Myers Squibb Co. 8-K filed 2022-01-10
“Vision supported by 4L+ data most recently presented at ASH 2021 iberdomide CC-92480” ✓ confirmed on the page
Market reaction: the shares moved +2.1% against the S&P 500 over the three sessions around the disclosure (7 Jan 2022 to 12 Jan 2022). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- ORR data for CELMoD agents
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Bristol Myers Squibb Co.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-BMY-004001 · Corrections policy